Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Olema Pharmaceuticals ( (OLMA) ) has provided an update.
On September 2, 2025, Olema Pharmaceuticals announced a new clinical trial collaboration with Pfizer to evaluate the combination of palazestrant and Pfizer’s investigational CDK4 inhibitor, atirmociclib, in a Phase 1b/2 study for ER+/HER2- metastatic breast cancer. This agreement marks Olema’s second collaboration with Pfizer, with the study aiming to assess the safety and combinability of the drug combination, potentially leading to a pivotal Phase 3 trial. Olema will lead the study, maintaining full global commercial and marketing rights to palazestrant, while Pfizer will supply atirmociclib.
The most recent analyst rating on (OLMA) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Olema Pharmaceuticals stock, see the OLMA Stock Forecast page.
Spark’s Take on OLMA Stock
According to Spark, TipRanks’ AI Analyst, OLMA is a Neutral.
Olema Pharmaceuticals faces substantial financial challenges with zero revenue and increasing losses, necessitating external funding. The technical analysis indicates some recent positive momentum, but the stock remains speculative due to negative profitability. The strategic collaboration with Novartis offers a positive outlook, potentially enhancing market position and supporting long-term growth. These factors collectively result in a moderate overall stock score.
To see Spark’s full report on OLMA stock, click here.
More about Olema Pharmaceuticals
Olema Pharmaceuticals, Inc., also known as Olema Oncology, is a clinical-stage biopharmaceutical company focused on developing targeted therapies for breast cancer. The company is advancing a pipeline of novel therapies, including its lead product candidate, palazestrant, which is an orally available complete estrogen receptor antagonist and selective ER degrader.
Average Trading Volume: 645,691
Technical Sentiment Signal: Hold
Current Market Cap: $374.7M
See more insights into OLMA stock on TipRanks’ Stock Analysis page.